Respiratory Assist Devices CPAP-BiPAP - Health Plan of Nevada
Respiratory Assist Devices CPAP-BiPAP - Health Plan of Nevada
Respiratory Assist Devices CPAP-BiPAP - Health Plan of Nevada
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
. Sleep oximetry demonstrates oxygen saturation less-than-or-equal-to 88% for<br />
at least five continuous minutes, done while breathing the individual’s usual<br />
FIO2, or<br />
c. Maximal inspiratory pressure for progressive neuromuscular disease is, less<br />
than 60 cm H20 or forced vital capacity is less than 50% predicted, and<br />
1. Chronic obstructive pulmonary disease (COPD) does not contribute<br />
significantly to the individual’s pulmonary limitation.<br />
2. If the above criteria are met, either an E0470 or E0471 device will be<br />
covered for individuals within this group <strong>of</strong> conditions for the first three<br />
months <strong>of</strong> NPPRA therapy.<br />
B. Severe COPD<br />
1. An arterial blood gas PaCO2, was done while individual was awake and breathing<br />
the individual’s usual FIO2, is greater-than-or-equal-to 52 mm Hg; and<br />
2. Sleep oximetry demonstrates oxygen saturation less-than-or-equal-to 88% for at<br />
least five continuous minutes, done while breathing oxygen at 2 liter per minute or<br />
the individual’s usual FIO2, whichever is higher; and<br />
3. Obstructive Sleep Apnea (OSA) (and treatment with <strong>CPAP</strong>) has been considered<br />
and ruled out prior to initiating therapy.<br />
4. If all <strong>of</strong> the above criteria for individuals with COPD are met, an E0470 device<br />
will be covered for the first three months <strong>of</strong> NPPRA therapy.<br />
5. An E0471 device will not be covered for an individual with COPD during the first<br />
two months, because therapy with an E0470 device with proper adjustments <strong>of</strong> the<br />
device’s setting and individual accommodation to its use will usually result in<br />
sufficient improvement without the need <strong>of</strong> a back-up rate.<br />
C. Central Sleep Apnea (CSA) or Complex Sleep Apnea (CompSA) (apnea not due to airway<br />
obstruction)<br />
1. Prior to initiating therapy, a complete facility-based, attended polysonigraph<br />
(PSG) must be performed documenting the following:<br />
a. The diagnosis <strong>of</strong> CSA or CompSA (see definitions in Appendices section);<br />
b. The ruling out <strong>of</strong> <strong>CPAP</strong> as effective therapy if either CSA or OSA is a<br />
component <strong>of</strong> the initially observed sleep-associated hypoventilation; and<br />
c. Significant improvement <strong>of</strong> the sleep-associated hypoventilation with the use<br />
<strong>of</strong> an E0470 or E0471 device on the settings that will be prescribed for initial<br />
use at home, while breathing the individual’s usual FIO2.<br />
2. If all above criteria are met, either an E0470 or E0471 device (based upon the<br />
judgment <strong>of</strong> the treating physician) will be covered for individuals with<br />
documented CSA or CompSA for the first three months <strong>of</strong> NPPRA therapy.<br />
Obstructive Sleep Apnea (OSA)<br />
1. A complete facility-based, attended polysomnogram, has established the diagnosis<br />
<strong>of</strong> obstructive sleep apnea according to the following criteria:<br />
a. The Apnea-Hypopnea Index (AHI) is greater-than-or-equal-to15 events per<br />
hour; or<br />
<strong>Respiratory</strong> <strong>Assist</strong> <strong>Devices</strong>_<strong>CPAP</strong>-<strong>BiPAP</strong> Page 2 <strong>of</strong> 9